XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 30.46

+2.2%

9:34 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (16067)	9/24/2002 10:25:56 PM
From: Robert K.	Read Replies (1) of 17367

Dr C. It aint bax that has bpi on a leash, its xoma itself. While bax could certainly do a whole lot more to develop bpi, IMO it is xomas fault. Remember bax only has rights to bpi-21, xoma can at anytime choose to develop any other part of the substancial molecule population, but instead they choose in in license other stuff. Nearly moronic. Next point. Hu1124 aint about "just" psoriasis. The platfom is substancial, and once they get that single indication the rest will be history. A good roadmap will be will amgen takes enbrel.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next